| Identification | Back Directory | [Name]
PF-CBP1 (hydrochloride) | [CAS]
2070014-93-4 | [Synonyms]
PF-CBP1 (hydrochloride)
HFOZCHHWLMTUTP-UHFFFAOYSA-N
5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[2-(morpholin-4-yl)ethyl]-2-[2-(4-propoxyphenyl)ethyl]-1H-1,3-benzodiazole
5-?(3,?5-Dimethyl-?4-?isoxazolyl)?-?1-?[2-?(4-?morpholinyl)?ethyl]?-?2-?[2-?(4-?propoxyphenyl)?ethyl]?-1H-?benzimidazole Hydrochloride | [Molecular Formula]
C29H37ClN4O3 | [MOL File]
2070014-93-4.mol | [Molecular Weight]
525.09 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
≥52.5 mg/mL in DMSO; insoluble in H2O; ≥40.6 mg/mL in EtOH | [form ]
solid | [color ]
White to yellow |
| Hazard Information | Back Directory | [Uses]
5-?(3,?5-Dimethyl-?4-?isoxazolyl)?-?1-?[2-?(4-?morpholinyl)?ethyl]?-?2-?[2-?(4-?propoxyphenyl)?ethyl]?-1H-?benzimidazole Hydrochloride is a potent and selective bromodomain of CREB binding protein (CBP BRD) inhibitor. 5-?(3,?5-Dimethyl-?4-?isoxazolyl)?-?1-?[2-?(4-?morpholinyl)?ethyl]?-?2-?[2-?(4-?propoxyphenyl)?ethyl]?-1H-?benzimidazole Hydrochloride downregulates inflammatory genes in macrophages and has therapeutic potential for treating neurological disorders. | [Biological Activity]
pf-cbp1 is a cbp/p300 bromodomain inhibitor.bromodomains are reported to be involved in transcriptional regulation via the recognition of acetyl lysine modifications. however, selective bromodomain modulators are still lacking, though the hydrophobic pocket makes bromodomains attractive targets. | [in vitro]
pf-cbp1 showed a significant reduction in brd4 potency, while retained cbp affinity. in order to evaluate compound-related cytotoxicity during gene transcription, primary macrophages were stimulated with lps and were further analyzed to determine the cell viability. results showed that pf-cbp1 and the negative control isox-inact did not cause cytotoxicity even at high concentrations up to 30 mm. in addition, pf-cbp1 at 10 mm was able to moderately reduce lps-induced il-6 and ifn-b expression, and a decrease in il-1b expression was observed at 3 mm. moreover, the rat primary cortical neurons were treated with pf-cbp1, vehicle, or the negative control isox-inact, and the results showed that at 1 hr, there were no changes in rgs4 expression compared with vehicle. however, the treatment of pf-cbp1 at 10-fold ic50 dose could significantly reduce rgs4 mrna levels at 24 hr when compared with that of vehicle [1]. | [IC 50]
125 and 363 nm for crebbp and p300 bromodomain, respectively | [storage]
Store at -20°C | [References]
[1] chekler el, et al. transcriptional profiling of a selective creb binding protein bromodomain inhibitor highlights therapeutic opportunities. chem biol. 2015 dec 17;22(12):1588-96. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
http://www.weikeqi-biotech.com/ |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|